A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides
Anna Wolska, Larry Lo, Denis Sviridov, Mohsen Pourmousa, Milton Pryor, Soumitra S. Ghosh, Rahul Kakkar, Michael Davidson, Sierra R. Wilson, Richard W. Pastor, Ira J. Goldberg, Debapriya Basu, Steven K. Drake, Antony Cougnoux, Ming Jing Wu, Saskia B. Neher, Lita A. Freeman, Jingrong Tang, Marcelo Amar, Matt Devalaraja, Alan T. Remaley
Abstract
) mice, confirming that it can also act independently of LPL. D6PV displayed good subcutaneous bioavailability of about 80% in nonhuman primates. Because it binds to high-density lipoproteins, which serve as a long-term reservoir, it also has an extended terminal half-life (42 to 50 hours) in nonhuman primates. In summary, D6PV decreases plasma TG by acting as a dual apoC-II mimetic and apoC-III antagonist, thereby demonstrating its potential as a treatment for HTG.